With the increasing need for GLP-1 medications, many patients find themselves dealing with a healthcare system that makes it easy to get prescriptions but often doesn’t provide personalized care. This can lead to strict dosing schedules, uncontrolled side effects, and limited support beyond just getting the medication filled. These issues can make it hard for patients to keep up with long-term weight loss goals. Ivim Health is introducing GLP-1 Individualized Dosing (GLP-1 ID), a method that offers more responsive, real-time care for patients using GLP-1 therapy. Based on Ivim’s nationally recognized care model, GLP-1 ID includes weekly dose adjustments led by providers and support that considers the entire patient, setting a new standard for safety, effectiveness, and long-term success in treating obesity.
“Every person reacts differently to GLP-1 medications. Even though we still offer fixed-dose plans, they are often too strict to handle side effects or adapt to how fast a patient’s body changes. Fixed-dose methods don’t offer the flexibility many patients need. With GLP-1 ID, we adjust the dose each week based on how the patient feels and how much progress they’re making. This often results in fewer side effects, better results, and a better chance that the patient will stay on the medication long enough to see real change,” explained Dr. Jessica Duncan, MD, Obesity Medicine Specialist at Ivim Health.
The GLP-1 ID program was inspired by a study published in Obesity Pillars in June 2025. The study looked at the outcomes of 1,131 patients who were treated through Ivim’s virtual GLP-1 program. These patients lost an average of 21.8% of their total body weight over 68 weeks, showing high retention and very few side effects. These results beat the outcomes seen in major clinical trials. While the study didn’t specifically look at GLP-1 ID, it confirmed the effectiveness of Ivim’s individualized care model. The positive results led to the creation of GLP-1 ID, which builds on that model by adding a formal system for weekly dose adjustments tailored to each patient’s biology, symptoms, and goals.
“The study clearly shows that individualized care improves GLP-1 treatment outcomes,” said Dr. Taylor Kantor, Chief Medical Officer and co-founder of Ivim Health. “With GLP-1 ID, we have created a structured, precise protocol that lets healthcare providers fine-tune dosing each week based on real-time patient feedback. Traditional treatments often keep patients stuck on fixed, standard doses. Our approach embraces true customization because every person’s response is unique, and their care should reflect that.”
An Ivim patient, Gbemisola Ogun, shared her experience: “Ivim is not like any other program I’ve tried. It wasn’t just about getting a prescription; it was about feeling truly supported. My provider took the time to understand my goals and adjusted my dose based on how my body reacted, which made a huge difference. The team regularly checked in and gave advice that fit my lifestyle. The nutrition guidance was practical, and the app helped me stay on track without added pressure. What really stood out was the personal touch—I always felt someone was there for me. Thanks to Ivim, I’ve lost weight and built healthier habits and a better relationship with myself. This program treated me as a whole person, not just a number.”
Health Technology Insights: Providers Express Frustration with Prior Authorization, Favor Real‑Time Tech Fix
Ivim Health has received over 25,000 five-star reviews on Trustpilot and is known as a leading GLP-1 telehealth provider in the United States. The launch of GLP-1 ID shows the company’s commitment to personalized care by offering patients a flexible, responsive option for weight management. By combining precise dosing, whole-body support, and clinical expertise, Ivim is raising the standard in obesity treatment. As the national conversation around GLP-1 therapies grows, Ivim remains committed to delivering care that adapts to the unique needs of each patient while focusing on outcomes driven by real data.
With the increasing need for GLP-1 medications, many patients find themselves dealing with a healthcare system that makes it easy to get prescriptions but often doesn’t provide personalized care. This can lead to strict dosing schedules, uncontrolled side effects, and limited support beyond just getting the medication filled. These issues can make it hard for patients to keep up with long-term weight loss goals. Today, Ivim Health is introducing GLP-1 Individualized Dosing (GLP-1 ID), a method that offers more responsive, real-time care for patients using GLP-1 therapy. Based on Ivim’s nationally recognized care model, GLP-1 ID includes weekly dose adjustments led by providers and support that considers the entire patient, setting a new standard for safety, effectiveness, and long-term success in treating obesity.
“Every person reacts differently to GLP-1 medications. Even though we still offer fixed-dose plans, they are often too strict to handle side effects or adapt to how fast a patient’s body changes. Fixed-dose methods don’t offer the flexibility many patients need. With GLP-1 ID, we adjust the dose each week based on how the patient feels and how much progress they’re making. This often results in fewer side effects, better results, and a better chance that the patient will stay on the medication long enough to see real change,” explained Dr. Jessica Duncan, MD, Obesity Medicine Specialist at Ivim Health.
The GLP-1 ID program was inspired by a study published in Obesity Pillars in June 2025. The study looked at the outcomes of 1,131 patients who were treated through Ivim’s virtual GLP-1 program. These patients lost an average of 21.8% of their total body weight over 68 weeks, showing high retention and very few side effects. These results beat the outcomes seen in major clinical trials. While the study didn’t specifically look at GLP-1 ID, it confirmed the effectiveness of Ivim’s individualized care model. The positive results led to the creation of GLP-1 ID, which builds on that model by adding a formal system for weekly dose adjustments tailored to each patient’s biology, symptoms, and goals.
“The study clearly shows that individualized care improves GLP-1 treatment outcomes,” said Dr. Taylor Kantor, Chief Medical Officer and co-founder of Ivim Health. “With GLP-1 ID, we have created a structured, precise protocol that lets healthcare providers fine-tune dosing each week based on real-time patient feedback. Traditional treatments often keep patients stuck on fixed, standard doses. Our approach embraces true customization because every person’s response is unique, and their care should reflect that.”
An Ivim patient, Gbemisola Ogun, shared her experience: “Ivim is not like any other program I’ve tried. It wasn’t just about getting a prescription; it was about feeling truly supported. My provider took the time to understand my goals and adjusted my dose based on how my body reacted, which made a huge difference. The team regularly checked in and gave advice that fit my lifestyle. The nutrition guidance was practical, and the app helped me stay on track without added pressure. What really stood out was the personal touch—I always felt someone was there for me. Thanks to Ivim, I’ve lost weight and built healthier habits and a better relationship with myself. This program treated me as a whole person, not just a number.”
Health Technology Insights: Lyra Health Study Finds AI Can Reduce Mental Health Care Costs Without Sacrificing Outcomes
Ivim Health has received over 25,000 five-star reviews on Trustpilot and is known as a leading GLP-1 telehealth provider in the United States. The launch of GLP-1 ID shows the company’s commitment to personalized care by offering patients a flexible, responsive option for weight management. By combining precise dosing, whole-body support, and clinical expertise, Ivim is raising the standard in obesity treatment. As the national conversation around GLP-1 therapies grows, Ivim remains committed to delivering care that adapts to the unique needs of each patient while focusing on outcomes driven by real data.
With the increasing need for GLP-1 medications, many patients find themselves dealing with a healthcare system that makes it easy to get prescriptions but often doesn’t provide personalized care. This can lead to strict dosing schedules, uncontrolled side effects, and limited support beyond just getting the medication filled. These issues can make it hard for patients to keep up with long-term weight loss goals. Today, Ivim Health is introducing GLP-1 Individualized Dosing (GLP-1 ID), a method that offers more responsive, real-time care for patients using GLP-1 therapy. Based on Ivim’s nationally recognized care model, GLP-1 ID includes weekly dose adjustments led by providers and support that considers the entire patient, setting a new standard for safety, effectiveness, and long-term success in treating obesity.
“Every person reacts differently to GLP-1 medications. Even though we still offer fixed-dose plans, they are often too strict to handle side effects or adapt to how fast a patient’s body changes. Fixed-dose methods don’t offer the flexibility many patients need. With GLP-1 ID, we adjust the dose each week based on how the patient feels and how much progress they’re making. This often results in fewer side effects, better results, and a better chance that the patient will stay on the medication long enough to see real change,” explained Dr. Jessica Duncan, MD, Obesity Medicine Specialist at Ivim Health.
The GLP-1 ID program was inspired by a study published in Obesity Pillars in June 2025. The study looked at the outcomes of 1,131 patients who were treated through Ivim’s virtual GLP-1 program. These patients lost an average of 21.8% of their total body weight over 68 weeks, showing high retention and very few side effects. These results beat the outcomes seen in major clinical trials. While the study didn’t specifically look at GLP-1 ID, it confirmed the effectiveness of Ivim’s individualized care model. The positive results led to the creation of GLP-1 ID, which builds on that model by adding a formal system for weekly dose adjustments tailored to each patient’s biology, symptoms, and goals.
“The study clearly shows that individualized care improves GLP-1 treatment outcomes,” said Dr. Taylor Kantor, Chief Medical Officer and co-founder of Ivim Health. “With GLP-1 ID, we have created a structured, precise protocol that lets healthcare providers fine-tune dosing each week based on real-time patient feedback. Traditional treatments often keep patients stuck on fixed, standard doses. Our approach embraces true customization because every person’s response is unique, and their care should reflect that.”
An Ivim patient, Gbemisola Ogun, shared her experience: “Ivim is not like any other program I’ve tried. It wasn’t just about getting a prescription; it was about feeling truly supported. My provider took the time to understand my goals and adjusted my dose based on how my body reacted, which made a huge difference. The team regularly checked in and gave advice that fit my lifestyle. The nutrition guidance was practical, and the app helped me stay on track without added pressure. What really stood out was the personal touch—I always felt someone was there for me. Thanks to Ivim, I’ve lost weight and built healthier habits and a better relationship with myself. This program treated me as a whole person, not just a number.”
Ivim Health has received over 25,000 five-star reviews on Trustpilot and is known as a leading GLP-1 telehealth provider in the United States. The launch of GLP-1 ID shows the company’s commitment to personalized care by offering patients a flexible, responsive option for weight management. By combining precise dosing, whole-body support, and clinical expertise, Ivim is raising the standard in obesity treatment. As the national conversation around GLP-1 therapies grows, Ivim remains committed to delivering care that adapts to the unique needs of each patient while focusing on outcomes driven by real data.
Health Technology Insights: ZAP Surgical Treats 5,000 Patients with ZAP-X Radiosurgery
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
